Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report)'s share price traded down 1.7% during mid-day trading on Friday . The company traded as low as $8.53 and last traded at $8.55. 116,945 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 1,073,353 shares. The stock had previously closed at $8.70.
Wall Street Analyst Weigh In
Several research firms have issued reports on DAWN. HC Wainwright decreased their price objective on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group cut their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating on the stock in a report on Monday, February 10th. JPMorgan Chase & Co. cut their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Wedbush restated an "outperform" rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $34.57.
Check Out Our Latest Stock Analysis on Day One Biopharmaceuticals
Day One Biopharmaceuticals Price Performance
The business has a fifty day moving average of $11.28 and a 200 day moving average of $12.96. The stock has a market cap of $834.05 million, a price-to-earnings ratio of -7.98 and a beta of -1.38.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analysts' expectations of $27.11 million. On average, analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.
Insider Buying and Selling at Day One Biopharmaceuticals
In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the transaction, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,064 shares of company stock worth $251,925 over the last 90 days. Insiders own 8.40% of the company's stock.
Institutional Investors Weigh In On Day One Biopharmaceuticals
Hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in Day One Biopharmaceuticals in the fourth quarter worth $27,000. R Squared Ltd bought a new position in Day One Biopharmaceuticals in the fourth quarter worth $31,000. Quest Partners LLC lifted its position in Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after purchasing an additional 7,668 shares during the period. Tower Research Capital LLC TRC lifted its position in Day One Biopharmaceuticals by 911.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock worth $135,000 after purchasing an additional 9,603 shares during the period. Finally, E Fund Management Co. Ltd. bought a new position in Day One Biopharmaceuticals in the fourth quarter worth $143,000. 87.95% of the stock is owned by institutional investors.
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Recommended Stories
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
